Cereblon is a direct protein target for immunomodulatory and antiproliferative activities of lenalidomide and pomalidomide
about
Pomalidomide is nonteratogenic in chicken and zebrafish embryos and nonneurotoxic in vitroA comprehensive review of lenalidomide in B-cell non-Hodgkin lymphomaNovel strategies to target the ubiquitin proteasome system in multiple myelomaRegulating the Regulators: Recent Revelations in the Control of E3 Ubiquitin LigasesNovel agents for multiple myeloma to overcome resistance in phase III clinical trialsNew drugs and novel mechanisms of action in multiple myeloma in 2013: a report from the International Myeloma Working Group (IMWG)Structure of the DDB1–CRBN E3 ubiquitin ligase in complex with thalidomideDrug resistance in multiple myeloma: latest findings and new concepts on molecular mechanisms.Cullin-RING ubiquitin E3 ligase regulation by the COP9 signalosomeA novel cereblon modulator recruits GSPT1 to the CRL4(CRBN) ubiquitin ligaseThe myeloma drug lenalidomide promotes the cereblon-dependent destruction of Ikaros proteinsLenalidomide causes selective degradation of IKZF1 and IKZF3 in multiple myeloma cellsImmunomodulatory effects in a phase II study of lenalidomide combined with cetuximab in refractory KRAS-mutant metastatic colorectal cancer patientsInhibition of the MDM2 E3 Ligase induces apoptosis and autophagy in wild-type and mutant p53 models of multiple myeloma, and acts synergistically with ABT-737A novel phthalimide derivative, TC11, has preclinical effects on high-risk myeloma cells and osteoclastsCRL4A(CRBN) E3 ubiquitin ligase restricts BK channel activity and prevents epileptogenesis.Chronic lymphocytic leukemia cells induce defective LFA-1-directed T-cell motility by altering Rho GTPase signaling that is reversible with lenalidomide.Pomalidomide for the treatment of relapsed-refractory multiple myeloma: a review of biological and clinical data.Expert panel consensus statement on the optimal use of pomalidomide in relapsed and refractory multiple myelomaImpact of pomalidomide therapy in multiple myeloma: a recent survey.Safety and efficacy of pomalidomide plus low-dose dexamethasone in STRATUS (MM-010): a phase 3b study in refractory multiple myelomaClinical Pharmacokinetics and Pharmacodynamics of Lenalidomide.Pomalidomide, Bortezomib and Dexamethasone (PVD) for Patients with Relapsed, Lenalidomide Refractory Multiple Myeloma.p97/VCP promotes degradation of CRBN substrate glutamine synthetase and neosubstrates.Pomalidomide for Symptomatic Kaposi's Sarcoma in People With and Without HIV Infection: A Phase I/II Study.Synergistic Cytotoxicity of Lenalidomide and Dexamethasone in Mantle Cell Lymphoma via Cereblon-dependent Targeting of the IL-6/STAT3/PI3K AxisExpression of cereblon protein assessed by immunohistochemicalstaining in myeloma cells is associated with superior response of thalidomide- and lenalidomide-based treatment, but not bortezomib-based treatment, in patients with multiple myeloma.Internal ribosome entry site of bFGF is the target of thalidomide for IMiDs development in multiple myeloma.Identification of cereblon-binding proteins and relationship with response and survival after IMiDs in multiple myeloma.Targeting Cullin-RING E3 ubiquitin ligases for drug discovery: structure, assembly and small-molecule modulation.Lenalidomide inhibits the proliferation of CLL cells via a cereblon/p21(WAF1/Cip1)-dependent mechanism independent of functional p53Novel insights into the mechanism of action of lenalidomide.Hijacking the E3 Ubiquitin Ligase Cereblon to Efficiently Target BRD4.Measuring cereblon as a biomarker of response or resistance to lenalidomide and pomalidomide requires use of standardized reagents and understanding of gene complexityLenalidomide induces lipid raft assembly to enhance erythropoietin receptor signaling in myelodysplastic syndrome progenitors.Protein ubiquitination in lymphoid malignancies.New insights, recent advances, and current challenges in the biological treatment of multiple myeloma.Overview of proteasome inhibitor-based anti-cancer therapies: perspective on bortezomib and second generation proteasome inhibitors versus future generation inhibitors of ubiquitin-proteasome system.RNA interference screening identifies lenalidomide sensitizers in multiple myeloma, including RSK2.Immunomodulatory agents lenalidomide and pomalidomide co-stimulate T cells by inducing degradation of T cell repressors Ikaros and Aiolos via modulation of the E3 ubiquitin ligase complex CRL4(CRBN.).
P2860
Q24634078-A418BCF3-2AB7-4D64-9BAC-60AFF53F4CBBQ26738937-DE496416-0087-48E7-A357-183B19C6D6DAQ26773246-6DE3E60F-B1F8-4436-9829-013955186FF9Q26799441-77E80F8F-7A69-44BE-84AE-A3BED711D2E0Q26822754-C10D20D3-BBB5-4873-863E-A33FB9CF5444Q27004421-1C5E3C32-16E8-454D-9B27-3552499362DBQ27684738-CBD4EBDA-4510-4684-8186-26EC3D64C01FQ27692033-4049DE0E-79F3-42C0-9684-82792C3DA3AAQ27704406-AEF950F9-460B-4D05-B757-FE047F1C393BQ27713259-AC5DFDA3-740C-40D6-A0C7-4A7FA7654624Q28303081-928A0A60-1C6A-429B-A5F9-6BF9563D9825Q28303091-2C4B8162-0EC9-4AB0-8829-9B4FA66FE61DQ28534976-049334F4-0152-4EE7-BC0A-BB0BFB3C123CQ28542684-B0C5D102-3769-4E36-8076-93F974E0330AQ28543087-290B9EA1-C62A-4EDF-8004-92FB5E305A9EQ30362741-48BA0D01-67E8-449B-B2EE-0EAEF9AFF45BQ30538420-94A3167F-D7D5-4ABE-947E-705929766800Q30802505-C8F5122C-8586-47F0-A6E4-F162CCB85095Q33413142-35FC5E12-23FE-46AD-9B31-2D174558DFAAQ33416346-C7AEA31F-4157-4CA2-A981-368CB5074058Q33432492-A8CB96CD-9988-49AB-A926-0CC48184CEB2Q33433453-C1F30B5A-996F-4D6B-8354-E9349BF23679Q33443411-CD9906DD-415E-4592-B64A-7535A05DEA9FQ33556826-4D6D7E99-1DDE-4911-9B3E-DFBADC13097DQ33816582-AA16497F-07E7-4B21-BE99-E7BE741E0023Q33817800-01879C80-0747-45A6-8263-A0F21B8D1A4EQ33846806-93FD2BA1-A1CE-4C28-A50A-599E8F8D7788Q33880085-CA195692-C03B-46B7-9DA1-9FD4490696E9Q33948719-B5500601-4896-4887-9B2F-E457A5F588EEQ34043797-B01E6B3A-6295-4645-81A3-CCFDA32C74B8Q34137016-E2937331-ED2A-4972-9A53-7222BE8FA455Q34373253-9F5B3805-5B64-4BCF-B6A6-7C267C29628AQ34479551-AA1D67EC-52E4-4FF0-BE88-FFD54CED5F7EQ34617633-B329FB1E-FE40-4D77-85D7-A94F37FBF1B3Q34627728-D188F5A7-1752-49AD-A723-3268B9CA4D82Q34722684-F7AA2159-3BC0-4CD3-992E-2C2ABC124A3BQ34773850-75416C02-9AE8-443B-B0CC-957ED625C5F5Q34788381-FD49B4F2-9E64-4F7B-B9C5-F8E4A647AC80Q34974049-97463283-DEA1-42A8-BF19-AD32E2EB3B97Q35064910-BA02B6E0-95A3-45FC-9866-0110FAD629DB
P2860
Cereblon is a direct protein target for immunomodulatory and antiproliferative activities of lenalidomide and pomalidomide
description
2012 nî lūn-bûn
@nan
2012 թուականի Նոյեմբերին հրատարակուած գիտական յօդուած
@hyw
2012 թվականի նոյեմբերին հրատարակված գիտական հոդված
@hy
2012年の論文
@ja
2012年論文
@yue
2012年論文
@zh-hant
2012年論文
@zh-hk
2012年論文
@zh-mo
2012年論文
@zh-tw
2012年论文
@wuu
name
Cereblon is a direct protein t ...... lenalidomide and pomalidomide
@ast
Cereblon is a direct protein t ...... lenalidomide and pomalidomide
@en
Cereblon is a direct protein t ...... lenalidomide and pomalidomide
@nl
type
label
Cereblon is a direct protein t ...... lenalidomide and pomalidomide
@ast
Cereblon is a direct protein t ...... lenalidomide and pomalidomide
@en
Cereblon is a direct protein t ...... lenalidomide and pomalidomide
@nl
prefLabel
Cereblon is a direct protein t ...... lenalidomide and pomalidomide
@ast
Cereblon is a direct protein t ...... lenalidomide and pomalidomide
@en
Cereblon is a direct protein t ...... lenalidomide and pomalidomide
@nl
P2093
P2860
P3181
P356
P1433
P1476
Cereblon is a direct protein t ...... lenalidomide and pomalidomide
@en
P2093
A K Gandhi
A Lopez-Girona
A Mahmoudi
P2860
P2888
P304
P3181
P356
10.1038/LEU.2012.119
P407
P50
P577
2012-05-03T00:00:00Z
P5875
P6179
1008299299